Tango Therapeutics, Inc. (TNGX)

Market Cap	617.85M
Revenue (ttm)	40.99M
Net Income (ttm)	-132.26M
Shares Out	108.39M
EPS (ttm)	-1.21
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	620,077
Open	5.74
Previous Close	5.65
Day's Range	5.64 - 5.96
52-Week Range	1.03 - 12.02
Beta	1.63
Analysts	Strong Buy
Price Target	12.20 (+114.04%)
Earnings Date	Aug 6, 2025

About TNGX

Tango Therapeutics, Inc., a precision oncology company, focuses on the discovery and development of drugs in defined patient populations with unmet medical need. The company develops methylthioadenosine -cooperative protein arginine methyltransferase 5 (PRMT5) inhibitors, including TNG462, which is in Phase 1/2 clinical trial for treating pancreatic and lung cancer; and TNG456, a brain-penetrant PRMT5 inhibitor for the treatment of glioblastoma. It is developing TNG260, a co-repressor of repressor element-1 silencing transcription inhibitor to ...

• Industry: Biotechnology
• Sector: Healthcare
• Founded: 2014
• Employees: 155
• Stock Exchange: NASDAQ
• Ticker Symbol: TNGX
• Website: https://www.tangotx.com

Financial Performance

In 2024, Tango Therapeutics's revenue was $42.07 million, an increase of 15.17% compared to the previous year's $36.53 million. Losses were -$130.30 million, 28.1% more than in 2023.

Analyst Summary

According to 6 analysts, the average rating for TNGX stock is "Strong Buy." The 12-month stock price target is $12.2, which is an increase of 114.04% from the latest price.

Price Target

$12.2

(114.04% upside)

Analyst Consensus: Strong Buy